These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 19818062)

  • 21. Effects of tolterodine ER on patient-reported outcomes in sexually active women with overactive bladder and urgency urinary incontinence.
    Rogers RG; Bachmann G; Scarpero H; Jumadilova Z; Sun F; Morrow JD; Guan Z; Bavendam T
    Curr Med Res Opin; 2009 Sep; 25(9):2159-65. PubMed ID: 19601704
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of fesoterodine on quality of life: pooled data from two randomized trials.
    Kelleher CJ; Tubaro A; Wang JT; Kopp Z
    BJU Int; 2008 Jul; 102(1):56-61. PubMed ID: 18564231
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Relationships between improvements in symptoms and patient assessments of bladder condition, symptom bother and health-related quality of life in patients with overactive bladder treated with tolterodine.
    Coyne KS; Elinoff V; Gordon DA; Deng DY; Brodsky M; Glasser DB; Jumadilova Z; Carlsson M
    Int J Clin Pract; 2008 Jun; 62(6):925-31. PubMed ID: 18479285
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Transcutaneous posterior tibial nerve electrostimulation with low dose trospium chloride: Could it be used as a second line treatment of overactive bladder in females.
    Abulseoud A; Moussa A; Abdelfattah G; Ibrahim I; Saba E; Hassouna M
    Neurourol Urodyn; 2018 Feb; 37(2):842-848. PubMed ID: 28792105
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical relevance of health-related quality of life outcomes with darifenacin.
    Abrams P; Kelleher C; Huels J; Quebe-Fehling E; Omar MA; Steel M
    BJU Int; 2008 Jul; 102(2):208-13. PubMed ID: 18325056
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Obesity is associated with a more severe overactive bladder disease state that is effectively treated with once-daily administration of trospium chloride extended release.
    Chancellor MB; Oefelein MG; Vasavada S
    Neurourol Urodyn; 2010 Apr; 29(4):551-4. PubMed ID: 19634167
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Correlation between improvements in Overactive Bladder Symptom Score and health-related quality of life questionnaires in overactive bladder patients treated with an antimuscarinic drug.
    Kubota Y; Kojima Y; Shibata Y; Imura M; Kohri K; Sasaki S
    Neurourol Urodyn; 2011 Sep; 30(7):1309-14. PubMed ID: 21560155
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Health-related quality of life of patients receiving extended-release tolterodine for overactive bladder.
    Kelleher CJ; Reese PR; Pleil AM; Okano GJ
    Am J Manag Care; 2002 Dec; 8(19 Suppl):S608-15. PubMed ID: 12516955
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Patient-reported outcomes in patients with overactive bladder treated with mirabegron and tolterodine in a prospective, double-blind, randomized, two-period crossover, multicenter study (PREFER).
    Herschorn S; Staskin D; Tu LM; Fialkov J; Walsh T; Gooch K; Schermer CR
    Health Qual Life Outcomes; 2018 Apr; 16(1):69. PubMed ID: 29673355
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The overactive bladder-symptom composite score: a composite symptom score of toilet voids, urgency severity and urge urinary incontinence in patients with overactive bladder.
    Zinner N; Harnett M; Sabounjian L; Sandage B; Dmochowski R; Staskin D
    J Urol; 2005 May; 173(5):1639-43. PubMed ID: 15821526
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score.
    Kaplan SA; Roehrborn CG; Chancellor M; Carlsson M; Bavendam T; Guan Z
    BJU Int; 2008 Nov; 102(9):1133-9. PubMed ID: 18510659
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Trospium chloride treatment of overactive bladder.
    Biastre K; Burnakis T
    Ann Pharmacother; 2009 Feb; 43(2):283-95. PubMed ID: 19193592
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Add-on fesoterodine for residual storage symptoms suggestive of overactive bladder in men receiving α-blocker treatment for lower urinary tract symptoms.
    Kaplan SA; Roehrborn CG; Gong J; Sun F; Guan Z
    BJU Int; 2012 Jun; 109(12):1831-40. PubMed ID: 21966995
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tolterodine extended release is efficacious in continent and incontinent subjects with overactive bladder.
    Rovner ES; Rackley R; Nitti VW; Wang JT; Guan Z;
    Urology; 2008 Sep; 72(3):488-93. PubMed ID: 18639327
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Trospium chloride improves overactive bladder symptoms: a multicenter phase III trial.
    Zinner N; Gittelman M; Harris R; Susset J; Kanelos A; Auerbach S;
    J Urol; 2004 Jun; 171(6 Pt 1):2311-5, quiz 2435. PubMed ID: 15126811
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Symptom bother and health-related quality of life outcomes following solifenacin treatment for overactive bladder: the VESIcare Open-Label Trial (VOLT).
    Garely AD; Kaufman JM; Sand PK; Smith N; Andoh M
    Clin Ther; 2006 Nov; 28(11):1935-46. PubMed ID: 17213014
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy of solifenacin in patients previously treated with tolterodine extended release 4 mg: results of a 12-week, multicenter, open-label, flexible-dose study.
    Chancellor MB; Zinner N; Whitmore K; Kobashi K; Snyder JA; Siami P; Karram M; Laramée C; Capo' JP; Seifeldin R; Forero-Schwanhaeuser S; Nandy I
    Clin Ther; 2008 Oct; 30(10):1766-81. PubMed ID: 19014833
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sustained improvement in patient-reported outcomes during long-term fesoterodine treatment for overactive bladder symptoms: pooled analysis of two open-label extension studies.
    Kelleher CJ; Dmochowski RR; Berriman S; Kopp ZS; Carlsson M
    BJU Int; 2012 Aug; 110(3):392-400. PubMed ID: 22129365
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Redefining response in overactive bladder syndrome.
    Payne CK; Kelleher C
    BJU Int; 2007 Jan; 99(1):101-6. PubMed ID: 17227496
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of Trospium Chloride on Cognitive Function in Women Aged 50 and Older: A Randomized Trial.
    Geller EJ; Dumond JB; Bowling JM; Khandelwal CM; Wu JM; Busby-Whitehead J; Kaufer DI
    Female Pelvic Med Reconstr Surg; 2017; 23(2):118-123. PubMed ID: 28067745
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.